How do you pay?

How to pay the least

Ask for the cash price

Xpovio

We didn’t find one.

  1. Ask your pharmacy for Xpovio’s cash price, and one or two other pharmacies too.
  2. Xpovio’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameXpovio
Authorized genericselinexor
Regular genericselinexor
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Xpovio?
The original
–
–

Brand nameThe maker’s card

XPOVIO Copay Program (KaryForward)

Savings card from Karyopharm Therapeutics

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $5 a prescription

The card takes up to $8,000 a month off your co-pay.

Sign up on xpovio.com 

Or call 1-844-243-7949.

In the maker’s words

“The XPOVIO® copay program may allow eligible patients with commercial insurance to pay as little as $5 per prescription, max amount is $8,000/month with an annual cap of $25,000. Other restrictions apply.”

From the maker’s offer on xpovio.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Xpovio itself, from the same company, sold without the brand name, and usually for less. For now Xpovio is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

XPOVIO is a nuclear export inhibitor indicated:

  • In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
  • In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Source: the FDA label for Xpovio (Karyopharm Therapeutics Inc.), May 12, 2026. Full label on DailyMed 

Good to know